Accumulating evidence demonstrates that HNF-1α/β dysfunction is pathologically implicated in metabolic disorders, with well-characterized mechanistic roles in nonalcoholic fatty liver disease (NAFLD), obesity-associated lipotoxicity, and atherosclerotic plaque formation(23–25). Here, HNF1A is linked to metabolic dysfunction-associated steatotic liver disease.